Literature DB >> 16627979

Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma.

Kan Gong1, Ning Zhang, Zheng Zhang, Yanqun Na.   

Abstract

Clear cell renal cell carcinoma (CCRCC) is the most common renal carcinoma and it is often associated with von Hippel-Lindau disease (VHL) gene mutations. CCRCCs with VHL mutations demonstrate hypoxia-inducible factor (HIF) overexpression as well as increased expression of vascular endothelial growth factor (VEGF). Recently, the erythropoietin (Epo) has been found to be upregulated in renal and other tumors associated with VHL disease. Furthermore, Epo and Epo receptor (EpoR) coexpression has also been reported in these tumors. The results provided strong evidence that an autocrine loop is involved in tumorigenesis in VHL disease. We investigated whether Epo and EpoR coexpression also occurs in sporadic CCRCC. Fifty-four sporadic CCRCCs were analyzed. VHL gene mutations were detected in 30 out of 54 tumors. Coexpression of Epo and EpoR was detected in 50 out of 54 tumors regardless of their VHL mutation status. The results suggest that coexpression of Epo and EpoR plays an important role in tumorigenesis of sporadic CCRCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627979     DOI: 10.4161/cbt.5.6.2709

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

Review 1.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

Review 2.  Systemic VHL gene functions and the VHL disease.

Authors:  Hannah L Bader; Tien Hsu
Journal:  FEBS Lett       Date:  2012-04-25       Impact factor: 4.124

3.  Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Authors:  Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre
Journal:  Tumour Biol       Date:  2016-07-28

4.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

5.  Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.

Authors:  Chen-chen Feng; Guan-xiong Ding; Ning-hong Song; Xuan Li; Zhong Wu; Hao-wen Jiang; Qiang Ding
Journal:  Tumour Biol       Date:  2013-06-19

6.  The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.

Authors:  Pengjie Wu; Ning Zhang; Xi Wang; Chi Zhang; Teng Li; Xianghui Ning; Kan Gong
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 7.  Functional significance of erythropoietin in renal cell carcinoma.

Authors:  Christudas Morais; David W Johnson; David A Vesey; Glenda C Gobe
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

8.  Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma.

Authors:  Daniel Beltrame Ferreira; Walter Henriques da Costa; Diego Abreu Clavijo; Ricardo Decia; Isabela Werneck Cunha; Luciana Schultz; Rafael Malagoli Rocha; Gustavo Cardoso Guimarães; Stênio de Cássio Zequi
Journal:  Kidney Cancer       Date:  2017-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.